🔗 Share this article

Given that America undertakes sweeping changes to its vaccine schedules, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccines during the global health crisis and has zeroed in on potential fatalities after Covid immunization in her short time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Health officials had intended to unveil sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, sources say – a significant shift that would place the US out of alignment with many the global community with no evidence for public health gain. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the division this calendar year.

A New Direction at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending some childhood immunization guidelines in the US to become more in line with Denmark, a nation with comprehensive healthcare and a population approximately the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

The appointee has no obvious background in pharmaceutical research, regulation or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Previous commissioners of CBER would “understand regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who led CBER have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the innovative therapies, but the generic program clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be looked after,” Dr. Woodcock said. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant leadership component to the job, which manages more than 5,000 employees. “It’s a massive leadership role, if you do it right,” Woodcock said.

Response and Contentious Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among FDA leaders on immunizations, a representative responded that the “questions are based on inaccurate premises”.

“Her resume matches the duties of her role,” the representative explained, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched expedited review system, a contentious one-day medication authorization process that reportedly troubled her predecessors. “By what process are these medications being picked for this fast-track system? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he said, “the agency looks to be trending towards laxer regulations of pharmaceuticals, with the exception of shots.”

Established Past Work on Immunizations

With immunizations, Dr. Høeg has a more documented, if problematic, track record, Howard said. She released a study using unverified volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Among her “policy goals” for the new government featured changing regulations for new vaccines and ending “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of excluding teenage boys from obtaining Covid vaccinations.

“She’s an complete dogmatist who commences with her beliefs and tailors the evidence to retrofit the science in a extremely disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|